^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    TPM2 (Tropomyosin 2)

    i
    Other names: Tropomyosin 2, Nemaline Myopathy Type 4, Tropomyosin Beta Chain, Tropomyosin 2 (Beta), NEM4, TMSB, DA1, Arthrogryposis Multiplex Congenital, Distal, Type 1, Epididymis Secretory Protein Li 273, Beta-Tropomyosin, Tropomyosin-2, HEL-S-273, AMCD1, DA2B4, DA2B, TPM2
    Associations

    News

    Trials
    24d
    Integrative Bioinformatics and Experimental Validation Establish CCNB1 as a Potential Biomarker for Diagnosis and Prognosis in Colorectal Cancer. (PubMed, Curr Issues Mol Biol)
    In vitro, CCNB1 knockdown triggered cell cycle arrest, thereby suppressing the proliferation of colorectal cancer cells. This study validated CCNB1 as a dual-purpose biomarker for CRC diagnosis and favorable prognosis, highlighting its potential utility in clinical management.
    Journal
    |
    TOP2A (DNA topoisomerase 2-alpha) • CDCA3 (Cell Division Cycle Associated 3) • CCNA2 (Cyclin A2) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • CDC20 (Cell Division Cycle 20) • KIF11 (Kinesin Family Member 11) • MCM4 (Minichromosome Maintenance Complex Component 4) • CCNB1 (Cyclin B1) • CDK3 (Cyclin Dependent Kinase 3) • CEP55 (Centrosomal Protein 55) • CKS2 (CDC28 Protein Kinase Regulatory Subunit 2) • CRYAB (Crystallin Alpha B) • MAD2L1 (Mitotic Arrest Deficient 2 Like 1) • MMP3 (Matrix metallopeptidase 3) • TPM2 (Tropomyosin 2) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)
    29d
    Targeting the Akt-EphA2 axis and cell-cell adhesion enhances anoikis sensitivity in cancer cells. (PubMed, Sci Rep)
    Pharmacological inhibition of Akt, EphA2, or ICAM1 in Tpm2.1-expressing cells significantly increases apoptosis under suspension conditions. These findings highlight that while rigidity sensing restoration alone may be insufficient to induce anoikis, it sensitizes cancer cells to targeted therapies, revealing actionable vulnerabilities to eliminate detached tumor cells.
    Journal
    |
    ICAM1 (Intercellular adhesion molecule 1) • TPM2 (Tropomyosin 2)
    3ms
    Using single cell sequencing to investigate tumor microenvironment differences in left and right colon cancer and prognosis-related core genes. (PubMed, Discov Oncol)
    Our prognosis-related risk model based on DEGs between RCC and LCC may provide better prediction of clinical outcomes for patients with colon cancer.
    Journal
    |
    TIMP1 (Tissue inhibitor of metalloproteinases 1) • LGALS4 (Galectin 4) • LY6E (Lymphocyte Antigen 6 Family Member E) • S100P (S100 calcium binding protein P) • TPM2 (Tropomyosin 2) • DNASE1L3 (Deoxyribonuclease 1 Like 3)
    3ms
    Development and validation of a machine learning-based prognostic model using mitochondrial dysfunction-related genes for colorectal cancer patients. (PubMed, Transl Cancer Res)
    This ML-based model using MRGs effectively predicts CRC prognosis, immune microenvironment, and therapeutic response, offering a framework for precision oncology. The 7-gene signature may guide risk stratification and targeted therapy, bridging mitochondrial biology with clinical outcomes.
    Journal • IO biomarker
    |
    NRG1 (Neuregulin 1) • GSTM1 (Glutathione S-transferase mu 1) • PPARGC1A (PPARG Coactivator 1 Alpha) • TPM2 (Tropomyosin 2)
    4ms
    Selective killing of cancer-associated fibroblasts by ultrasound-mediated mechanical forces. (PubMed, Biomaterials)
    Further, 3D gel contractility and migration assay confirm that a prolonged US treatment disrupts myosin IIA-mediated contractility, which CAFs primarily use to support cancer invasion. Since US treatment causes mechanoptosis and reduces contractility, this approach could be used to develop ultrasound-based CAF-targeting therapy to augment cancer treatment.
    Journal
    |
    MIR21 (MicroRNA 21) • TPM2 (Tropomyosin 2)
    4ms
    Construction of a prognostic model for colorectal cancer liver metastasis based on single-cell transcriptomics and regulation of the MIF pathway. (PubMed, Front Oncol)
    During liver metastasis in colorectal cancer, the expression levels of TPM2, RPS17, and TNNT1 were significantly elevated, SPINK4 expression was reduced in the epithelial cells. Furthermore, the interaction between the MIF pathway and its ligands, CD74/CXCR4, may play a important role in promoting tumor metastasis.
    Journal
    |
    CD74 (CD74 Molecule) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • TPM2 (Tropomyosin 2)
    6ms
    Spatial gene expression profiling identifies prognostic features of residual tumors after neoadjuvant chemotherapy in triple-negative breast cancer. (PubMed, Front Oncol)
    We identified some differentially expressed genes relevant to oncogenic signaling and immunosuppressive tumor-associated macrophages. These findings provide novel insights into factors affecting prognosis in patients with residual disease after NAC for early-stage TNBC.
    Journal
    |
    ACTA2 (Actin Alpha 2 Smooth Muscle) • S100A9 (S100 Calcium Binding Protein A9) • CHI3L1 (Chitinase 3-like 1) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • COL1A1 (Collagen Type I Alpha 1 Chain) • HLA-DPA1 (Major Histocompatibility Complex, Class II, DP Alpha 1) • KRT14 (Keratin 14) • COL3A1 (Collagen Type III Alpha 1 Chain) • IFI27 (Interferon Alpha Inducible Protein 27) • AZGP1 (Alpha-2-Glycoprotein 1, Zinc-Binding) • MMP7 (Matrix metallopeptidase 7) • MYLK (Myosin Light Chain Kinase) • PABPC1 (Poly(A) Binding Protein Cytoplasmic 1) • SERPINA3 (Serpin Family A Member 3) • TPM2 (Tropomyosin 2) • RPL22 (Ribosomal Protein L22)
    6ms
    Tropomyosin isoforms encoded by TPM2 control the actin-bundling activity of fascin-1. (PubMed, Biol Res)
    Cytoplasmic Tpm2 isoforms regulate actin bundling activity of fascin-1 by organizing protein composition in the bundles, a mechanism that may contribute to the suppression of metastatic phenotype in cancer cells.
    Journal
    |
    TPM2 (Tropomyosin 2)
    6ms
    A novel anoikis related gene prognostic model for colorectal cancer based on single cell sequencing and bulk transcriptome analyses. (PubMed, Sci Rep)
    A 10 anoikis-related-gene prognostic model (MGP, TPM2, CRIP2, TUBB6, C1orf54, NOTCH3, LTBP1, CSRP2, FSTL3, and VIM) was developed and the area under the curve (AUC) values of the model in predicting 1-, 3- and 5-year survival probabilities reached 0.744, 0.797, and 0.755, respectively. In conclusion, anoikis related genes could be promising prognostic factors for risk stratification of CRC patients.
    Journal
    |
    NOTCH3 (Notch Receptor 3) • LTBP1 (Latent-transforming growth factor beta-binding protein 1) • TPM2 (Tropomyosin 2)
    7ms
    Bioinformatics analysis to identify endocrine-disrupting chemicals targeting key ESCC-related genes. (PubMed, Toxicol Mech Methods)
    Based on these genes, 25 EDCs potentially involved in ESCC were identified, of which 13 (such as benzo[a]pyrene) targeted at least three of the key genes. These findings suggested a novel EDC-gene-ESCC interaction network and provide insights into the environmental mechanisms underlying ESCC, offering potential targets for risk assessment and therapeutic intervention.
    Journal
    |
    KRT17 (Keratin 17) • SALL4 (Spalt Like Transcription Factor 4) • ADH1B (Alcohol Dehydrogenase 1B (Class I), Beta Polypeptide) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • TPM2 (Tropomyosin 2)
    7ms
    E26 transformation-specific transcription factor 3 tips the balance: repressing tropomyosin 2 to fuel Yes-associated protein 1-driven cisplatin resistance in ovarian cancer. (PubMed, Anticancer Drugs)
    These findings highlight the ELK3/TPM2/YAP1 axis as a critical regulator of cisplatin resistance. By suppressing TPM2 and subsequently activating YAP1 signaling, our study identified ELK3 as a crucial transcriptional repressor that contributes to cisplatin resistance in ovarian cancer.
    Journal
    |
    YAP1 (Yes associated protein 1) • TCF3 (Transcription Factor 3) • TPM2 (Tropomyosin 2)
    |
    cisplatin
    8ms
    Development and interpretation of a pathomics-driven ensemble predictive model for prognosis of intrahepatic cholangiocarcinoma. (PubMed, Eur J Surg Oncol)
    This study initially developed an ensemble pathomics model for the prognosis of iCCA, which could help make individualized treatment postoperatively. Moreover, we employed various methods to improve the interpretation of the model.
    Journal
    |
    PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2) • TPM2 (Tropomyosin 2)